ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

ClearPoint Neuro, Inc.

BrainCo develops brain-machine interface technologies aimed at enhancing possibilities in rehabilitation, health, and education.

BrainCo

Our mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of our current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in 60+ Clinical & Research Centers in the US, Canada, & EU... and growing globally. ClearPoint Neuro’s SmartFlow® cannula is being used in partnership or evaluation with 30+ individual biologics and drug delivery companies in various stages, from preclinical research to late stage regulatory trials. To date, more than 4,000 cases have been performed and supported by our field-based Clinical Specialist team which offers support and services for our partners.

Hear the remarkable story of 3-year-old AADC Deficiency patient Simone. In May, he underwent the first commercial brain gene therapy procedure in Italy using ClearPoint’s SmartFlow cannula with our MRI-guided navigation platform. #CLPT #AADCdefiency #GeneTherapy #Nsgy #SmartFlow - https://loom.ly/rIn9EQE

To wrap up #WorldQualityWeek we're delighted to celebrate our amazing #Quality team. Since 2021 they have completed 15 successful audits, achieved MDSAP certification, Anvisa approval of our portfolio in Brazil, as well as approval by the State of California for our new Carlsbad manufacturing facility. #CLPT

ClearPoint Neuro reports Third Quarter 2023 results -  Biologics & Drug Delivery growing 55%; Q3 operational cash burn of $1.8M #CLPT
 bit.ly/3SzHjVF

Thanks to everyone who attended Lyubomir Zagorchev, PhD's  presentation yesterday & reach out if you’d like to learn more about our solutions for segmentation of subcortical structures and infusion coverage analysis. We look forward to another day of sessions at the Hanson Wade Group Gene Therapy for Neurological Disorders conference. #CLPT

Are you attending the Hanson Wade Group Gene Therapy for Neuro conference in Boston starting tomorrow? Join us to hear Lyubomir Zagorchev, PhD present on Analysis of Intraparenchymal Delivery in Clinical Trials and Preclinical Studies, and stop by our exhibit table to meet with the ClearPoint team! #CLPT

We are honored the ClearPoint #Prism Neuro Laser Therapy System is included at this weekend’s #ASSFN Neurosurgical Stereotactic & Functional Hands-On course at the University of Colorado Anschutz Medical Campus. Residents & fellows will learn the #ClearPoint workflow for laser and #DBS from our Director of Education & Training, Kara Kittelberger, PhD. Thanks to Daniel Schoenecker & Kara for supporting this course! #Nsgy #MedicalEducation #CLPT

#ClearPoint is proud to have supported 1660+ cases so far guiding #LaserTherapy, #DBS, & #DrugDelivery in #ClinicalTrials to treat drug-resistant #Epilepsy. With our ClearPoint #Prism Neuro Laser Therapy System, we’re delighted to offer our 1st therapeutic device to help epilepsy patients. #NEAM2023 #EpilepsyAwareness #Nsgy #CLPT

For October’s employee highlight, we’ve chosen to celebrate #Production Manager, Sean Nakaoka! We’re grateful to have such a knowledgeable and dedicated manager supporting our Carlsbad-based #Operations on the #ClearPoint team. #ProductionManager #Manufacturing #EmployeeHighlight #CLPT

ClearPoint Neuro to announce Third Quarter 2023 results November 9, 2023 after market close. https://lnkd.in/giBdxBa4 #CLPT bit.ly/3FwbXHW

Thanks to everyone who stopped by our #ESGCT2023 posters last night, and we look forward to another session tonight. Find us at Booth 38 if you’re at the conference, or reach out if you’d like to receive a digital copy of any of the #ClearPoint posters.
#CellTherapy #GeneTherapy #CLPT

Metric
Company Name	ClearPoint Neuro, Inc.	BrainCo
Symbol	CLPT
MSH ID	COM:CLEARPOINTNEURO	CN:BRAINCO
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Medical - Devices	Medical Devices
Country	US	CN
Stage		Seed
Employee Count	107
Website	clearpointneuro.com	brainco.cn
LinkedIn	clearpointneuro	brainco
Founders

Metric
Market Cap	198.25M
Enterprise Value
Monthly Web Traffic		4.67K
Web Traffic Growth		0.42
Valuation
Raised Capital		5.50M

Metric
Revenue	23.95M
Revenue (LTM)
Revenue (NTM)
Gross Profit	13.61M
EBITDA	-20.99M
Operating Income	-22.45M
Net Income	-22.09M
EPS	-0.90
Diluted EPS	-0.90
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.60
Operating Profit Margin	-0.66
EBITDA Margin	-0.88
Net Profit Margin	-0.64
Return on Equity	-0.64
Return on Assets	-0.34
Return on Capital Employed	-0.52

COM:CLEARPOINTNEURO

ClearPoint Neuro

Last Close

11.09

22/11 21:00

Market Cap

198.25M

Beta: -

Volume Today

327.16K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.51
P/B Ratio	7.62
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	13.23
EV Multiple	-7.23

Metric
Days Sales Outstanding	39.64
Days Payables Outstanding	30.63
Days Inventory Outstanding	279.23
Operating Cycle	339.32
Cash Conversion Cycle	325.45
Asset Turnover	0.56

Metric
Operating Cash Flow	-13.72M
Free Cash Flow	-14.77M
Cash Flow to Debt	-0.49
Operating Cash Flow/Sales	-0.24
Free Cash Flow Yield	-0.09

Metric
Cash & Equivalents	23.14M
Accounts Receivable	-1.80M
Inventory	7.91M
Goodwill
Debt to Capitalization	0.33
Debt to Assets	0.32
Current Ratio	6.68
Quick Ratio	3.65

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.26
R&D to Revenue	0.57
SG&A to Revenue	0.45